Compare NEO & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEO | ATRC |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2008 | 2005 |
| Metric | NEO | ATRC |
|---|---|---|
| Price | $16.90 | $58.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | $23.40 | ★ $60.44 |
| AVG Volume (30 Days) | ★ 1.9M | 741.7K |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.74 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $201,630,000.00 |
| Revenue This Year | $11.12 | $13.42 |
| Revenue Next Year | $9.68 | $12.24 |
| P/E Ratio | ★ N/A | $242.70 |
| Revenue Growth | N/A | ★ 15.40 |
| 52 Week Low | $7.07 | $25.36 |
| 52 Week High | $20.15 | $66.02 |
| Indicator | NEO | ATRC |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 49.44 |
| Support Level | $15.73 | $55.16 |
| Resistance Level | $17.19 | $61.70 |
| Average True Range (ATR) | 0.86 | 2.80 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 29.78 | 27.84 |
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.